Helicobacter Pylori CagA Promotes Gastric Cancer Immune Escape by Upregulating SQLE

Overview

Journal Cell Death Dis

Date 2025 Jan 14

PMID 39809787

Authors

Sifan Liu

Nan Zhang

Xu Ji

Shuyue Yang

Zheng Zhao

Peng Li

Affiliations

Soon will be listed here.

Abstract

Helicobacter pylori (H. pylori) infection is a well-established risk factor for gastric cancer, primarily due to its virulence factor, cytotoxin-associated gene A (CagA). Although PD-L1/PD-1-mediated immune evasion is critical in cancer development, the impact of CagA on PD-L1 regulation remains unclear. This study revealed that H. pylori CagA upregulated squalene epoxidase (SQLE) expression, a key enzyme in the cholesterol biosynthesis pathway. Elevated SQLE activity increased cellular palmitoyl-CoA levels, enhancing PD-L1 palmitoylation while decreasing its ubiquitination. This ultimately increases PD-L1 stability, suppressing T cell activity and facilitating immune evasion in gastric cancer. In summary, our findings highlight the crucial role of the CagA-SQLE-PD-L1 axis in gastric cancer progression, suggesting potential therapeutic strategies for targeting CagA-positive gastric cancer.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Yao L, Li J, Zhang X, Zhou L, Hu K . Downregulated ferroptosis-related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma. CNS Neurosci Ther. 2022; 28(12):2104-2115. PMC: 9627366. DOI: 10.1111/cns.13945. View

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

Akinleye A, Rasool Z . Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019; 12(1):92. PMC: 6729004. DOI: 10.1186/s13045-019-0779-5. View

Lee T, Tsai E, Liu S, Hsu Hung S, Chang S, Chao C . Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy. Cancer Res. 2024; 84(6):800-807. PMC: 10940856. DOI: 10.1158/0008-5472.CAN-23-2664. View

Kim Y, Lee S, Kim S, Jang H, Hwang I, Jin S . Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation. Nat Chem Biol. 2019; 15(9):907-916. DOI: 10.1038/s41589-019-0344-0. View

Wang Q, Cao Y, Shen L, Xiao T, Cao R, Wei S . Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs. Sci Adv. 2022; 8(34):eabq4722. PMC: 9417176. DOI: 10.1126/sciadv.abq4722. View

Hu L, Huang W, Wang X, Xu C, Qin W, Li D . Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression. Mol Ther. 2022; 30(10):3284-3299. PMC: 9552806. DOI: 10.1016/j.ymthe.2022.06.015. View

Piccolo S, Dupont S, Cordenonsi M . The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014; 94(4):1287-312. DOI: 10.1152/physrev.00005.2014. View

10.

Correa P, Houghton J . Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007; 133(2):659-72. DOI: 10.1053/j.gastro.2007.06.026. View

11.

Li N, Feng Y, Hu Y, He C, Xie C, Ouyang Y . Helicobacter pylori CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway. J Exp Clin Cancer Res. 2018; 37(1):280. PMC: 6251132. DOI: 10.1186/s13046-018-0962-5. View

12.

Yao H, Lan J, Li C, Shi H, Brosseau J, Wang H . Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019; 3(4):306-317. DOI: 10.1038/s41551-019-0375-6. View

13.

Shangguan X, Ma Z, Yu M, Ding J, Xue W, Qi J . Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer. Cancer Res. 2022; 82(17):3032-3044. DOI: 10.1158/0008-5472.CAN-21-3822. View

14.

Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P . CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017; 549(7670):101-105. PMC: 5706633. DOI: 10.1038/nature23643. View

15.

Polk D, Peek Jr R . Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10(6):403-14. PMC: 2957472. DOI: 10.1038/nrc2857. View

16.

Yang Z, Qi Y, Lai N, Zhang J, Chen Z, Liu M . Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. J Exp Clin Cancer Res. 2018; 37(1):1. PMC: 5755139. DOI: 10.1186/s13046-017-0664-4. View

16.

Molina-Castro S, Tiffon C, Giraud J, Boeuf H, Sifre E, Giese A . The Hippo Kinase LATS2 Controls Helicobacter pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa. Cell Mol Gastroenterol Hepatol. 2019; 9(2):257-276. PMC: 6957828. DOI: 10.1016/j.jcmgh.2019.10.007. View

17.

Du Y, Rokavec M, Hermeking H . Squalene epoxidase/SQLE is a candidate target for treatment of colorectal cancers with mutation and elevated c- expression. Int J Biol Sci. 2023; 19(13):4103-4122. PMC: 10496509. DOI: 10.7150/ijbs.85724. View

18.

Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C . infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2021; 71(3):457-466. PMC: 8862014. DOI: 10.1136/gutjnl-2020-323392. View

19.

Li C, Wang Y, Liu D, Wong C, Coker O, Zhang X . Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut. 2022; 71(11):2253-2265. PMC: 9554078. DOI: 10.1136/gutjnl-2021-325851. View